Stockscreener 앱 받기
0.517
0.08%
0.0004
시장 영업 전:
.50
-0.017
-3.29%
전일 마감가:
$0.5166
열려 있는:
$0.5228
하루 거래량:
46,458
Relative Volume:
0.01
시가총액:
$4.21M
수익:
$88,000
순이익/손실:
$-13.96M
주가수익비율:
-0.0777
EPS:
-6.6545
순현금흐름:
$-11.34M
1주 성능:
-0.58%
1개월 성능:
-13.11%
6개월 성능:
-71.09%
1년 성능:
+445.33%
1일 변동 폭
$0.5101
$0.5228
1주일 범위
$0.5021
$0.5359
52주 변동 폭
$0.475
$20.33
AIM ImmunoTech Inc Stock (AIM) Company Profile
명칭
AIM ImmunoTech Inc
전화
352 448 7797
주소
2117 SW Highway 484, Ocala, FL
Compare AIM vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AIM
AIM ImmunoTech Inc
|
0.517 | 4.21M | 88,000 | -13.96M | -11.34M | -6.6545 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
AIM ImmunoTech Inc 주식(AIM)의 최신 뉴스
AIM ImmunoTech (AIM) price target decreased by 54.50% to 10.20 - MSN
AIM Stock Price, Quote & Chart | AIM IMMUNOTECH INC (NYSEARCA:AIM) - ChartMill
AIM ImmunoTech Inc. Common Stock (NY: AIM - FinancialContent
AIM ImmunoTech Inc. (AIM) posts wider than expected Q4 2025 loss, yet shares rise modestly in today’s trading.Most Watched Stocks - Cổng thông tin điện tử tỉnh Tây Ninh
AIM ImmunoTech Appoints David Chemerow to Board of Directors as an Independent Director - The National Law Review
AIM ImmunoTech Enters Pivotal Value Inflection Phase with Planned Phase 3 Study of Ampligen® in Pancreatic Cancer, Backed by Positive Clinical Signals, Orphan Drug Status, and Global IP - ADVFN
AIM ImmunoTech advances Phase 3 planning for pancreatic cancer By Investing.com - Investing.com Australia
AIM ImmunoTech (AIM) Advances Pancreatic Cancer Treatment Plans - GuruFocus
AIM ImmunoTech IncExpects Next Duripanc St - Moomoo
AIM ImmunoTech Starts Late-Stage Trial of Ampligen in Pancreatic Cancer - Moomoo
AIM ImmunoTech advances Phase 3 planning for pancreatic cancer - Investing.com
AIM ImmunoTech Enters Pivotal Value Inflection Phase with - GlobeNewswire
AIM ImmunoTech Inc. announces that its core drug Ampligen® has reached a critical value inflection point in the field of pancreatic cancer treatment. - Bitget
AIM ImmunoTech Provides Routine Update on Annual Filings - ChartMill
AIM ImmunoTech Inc. Reports Audit Findings with Going Concern Emphasis and Positive Clinical Trial Progress for Ampligen in Pancreatic Cancer Treatment - Quiver Quantitative
Aim Immunotech Provides Routine Update On Annual Filings - TradingView
AIM ImmunoTech Inc. 8-K Filing Details Equity Distribution Agreement Amendment and NYSE American Listing - Minichart
AIM ImmunoTech Expands At-The-Market Equity Offering Capacity - TipRanks
AIM ImmunoTech's ATM Expansion Hides Ongoing Liquidity Stress and Shareholder Squeeze Risk - Bitget
AIM ImmunoTech amends equity distribution agreement to remove share sale limit - Investing.com Australia
AIM ImmunoTech Expands ATM Equity Program With Maxim, Removing Prior $3 Million Cap - TradingView
AIM ImmunoTech (NYSE: AIM) lifts cap on at-the-market stock sales - Stock Titan
AIM ImmunoTech (NYSE American: AIM) ups ATM capacity to $3.41M under S‑3 - Stock Titan
Constellation Brands To Rally More Than 13%? Here Are 10 Top Analyst Forecasts For Friday - Benzinga
AIM Stock Target Price Lowered by Ascendiant Capital | AIM Stock News - GuruFocus
AIM ImmunoTech to Participate in Live Virtual Investor Closing Bell Event - marketscreener.com
AIM ImmunoTech CEO to take live investor questions on April 16 - Stock Titan
AIM SEC FilingsAim Immunotech 10-K, 10-Q, 8-K Forms - Stock Titan
AIM ImmunoTech Inc (AIM) Stock Price, Trades & News - GuruFocus
AIM Stock Analysis: AIM ImmunoTech Inc. hits 0.59 on 8.18 percent biotech rally - Xã Thanh Hà
AIM ImmunoTech Inc. (AIM) Stock Price, News, Quote & History - Yahoo! Finance Canada
Is AIM ImmunoTech (AIM) stock outpacing its medical peers this year? - MSN
AIM PE Ratio & Valuation, Is AIM Overvalued - Intellectia AI
AIM Stock Analysis: AIM ImmunoTech Inc. biotech performance update at 0.59 after minor daily advance - Cổng thông tin điện tử Tỉnh Sơn La
AIM ImmunoTech 2025 Annual Report: Focus on Ampligen for Pancreatic Cancer, Clinical Trials, and R&D Highlights - Minichart
AIM ImmunoTech 10-K: $0.09M Revenue, $(8.62) EPS, $13.96M Net Loss - TradingView — Track All Markets
AIM ImmunoTech Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - MarketScreener
Going concern risk and oncology plans at AIM ImmunoTech (AIM) detailed - Stock Titan
What's going on with AIM ImmunoTech stock Friday? - msn.com
AIM ImmunoTech Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
Earnings Scheduled For March 24, 2026 - Sahm
Thermo Fisher Scientific (TMO) Partners With AIM ImmunoTech on Phase 3 Cancer Trial - Insider Monkey
If You Invested $1,000 in Aim Immunotech (AIM) - Stock Titan
AIM ImmunoTech Inc (AIM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.14%
0.48%
자본화:
|
볼륨(24시간):